Why the study?
Does bivalirudin reduce thrombotic events and mortality compared to unfractionated heparin in adult patients supported by extracorporeal membrane oxygenation?
Population
Adult patients supported by extracorporeal membrane oxygenation (ECMO)
Comparison
Bivalirudin for systemic anticoagulation vs Unfractionated heparin for systemic…
Design
Cohort
Follow-up
30-day
Authors
Loading...
Bivalirudin may serve as alternative to heparin in adult ECMO; leaves open superiority in randomized trials.
Does bivalirudin reduce thrombotic events and mortality compared to unfractionated heparin in adult patients supported by extracorporeal membrane oxygenation?
Bivalirudin is a viable alternative to unfractionated heparin for systemic anticoagulation in adult ECMO patients, but it does not offer a clinically significant advantage in reducing thrombotic events or mortality.
Berei et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: